Experimental cell therapy takes on deadly brain tumors
NCT ID NCT07496073
First seen Mar 27, 2026 · Last updated Jun 13, 2026 · Updated 12 times
Summary
This early-phase study tests a new cell therapy called CHT101 in 30 adults whose malignant brain tumors have come back or worsened after standard treatment. The therapy uses specially engineered cells to target a protein called CD70 found on tumor cells. The main goal is to check safety and how the body handles the treatment, with early signs of tumor shrinkage also being tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN (NERVOUS SYSTEM) CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.